DexCom Q2 2026 Earnings Report

DexCom EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.61
• Beat/Miss: N/A
• One Year Ago EPS: N/A

DexCom Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.29 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

DexCom Announcement Details

• Quarter: Q2 2026
• Date: 7/29/2026
• Time: After Market Closes
• Conference Call Date: Thursday, July 30, 2026
• Conference Call Time: 4:30PM ET

DexCom (NASDAQ:DXCM) is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations. The company’s product portfolio includes commercially marketed systems—most notably its G6 and G7 families—which are intended to simplify sensor insertion, extend wearable life and improve ease of use. These systems are used in both personal and professional settings, including by patients at home and by clinicians who monitor glucose remotely.

DexCom’s CGM ecosystem emphasizes connectivity and interoperability. Its devices support mobile apps for real-time glucose display and data sharing with caregivers, and are designed to integrate with insulin delivery systems and other digital health platforms to enable automated or guided diabetes management workflows. The company also invests in software and data analytics to enhance actionable insights for users and providers.

Operating commercially in the United States and across multiple international markets, including Europe and parts of the Asia‑Pacific region, DexCom pursues expanded access through reimbursement initiatives, partnerships and regulatory approvals. The company has emphasized ongoing research and development aimed at improving sensor accuracy, user convenience and the broader clinical applications of continuous glucose monitoring. It is led by CEO Kevin Sayer and a management team focused on device innovation and global commercial growth.